Compare IBCP & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBCP | DRUG |
|---|---|---|
| Founded | 1864 | 2019 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.4M | 707.1M |
| IPO Year | 2010 | 2020 |
| Metric | IBCP | DRUG |
|---|---|---|
| Price | $34.46 | $87.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $36.67 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 177.2K | 137.4K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 3.48 | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $32,075,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.98 | N/A |
| P/E Ratio | $10.63 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $29.37 | $23.18 |
| 52 Week High | $37.39 | $123.75 |
| Indicator | IBCP | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 67.34 |
| Support Level | $29.95 | $69.83 |
| Resistance Level | $34.71 | $91.00 |
| Average True Range (ATR) | 0.66 | 5.15 |
| MACD | 0.27 | 2.08 |
| Stochastic Oscillator | 81.24 | 99.61 |
Independent Bank Corp. operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers. The firm's principal markets are the rural and suburban communities across Lower Michigan. The firm generates the majority of its revenue from Interest and fees on loans.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.